Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD 2.050
+0.030 (1.49%)
Jun 5, 2026, 4:10 PM AEST
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
1.21M AUD
Profits / Employee
-1.75M AUD
Market Cap
2.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mesoblast News
- 6 days ago - Mesoblast Slides: Investor presentation - Filings
- 5 weeks ago - Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil® - GuruFocus
- 5 weeks ago - Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - GlobeNewsWire
- 5 weeks ago - Mesoblast Earnings release: Q3 2026 - Filings
- 5 weeks ago - Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 7 weeks ago - Mesoblast acquires chimeric antigen receptor platform technology - TheFly
- 7 weeks ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire
- 2 months ago - Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION - GlobeNewsWire